Related Experiment Videos
Neutralizing antibodies reduce MxA protein induction in interferon-beta-1a-treated MS patients
A-M Vallittu1, M Halminen, J Peltoniemi
1Department of Virology, Turku Immunology Centre and University of Turku, Finland. anna-maija.vallittu@utu.fi
Background:
Neutralizing antibodies (NAb) during interferon-beta (IFNbeta) treatment of MS are associated with reduced clinical and MR efficacy. NAb inhibit the IFN- inducible MxA gene expression and neutralize the capability of IFNbeta to inhibit virus growth in vitro. Presently, there is no clear concept of the biologic importance of IFNbeta antibodies; most of the tests applied for the detection of NAb in previous publications are not widely available, and the results are not fully comparable.
Methods:
A 1-year prospective study of the development of binding antibodies (BAb) and NAb and their relationship to IFN-inducible MxA protein levels in peripheral blood leukocytes in 20 IFNbeta-1a-treated patients with relapsing-remitting MS was conducted.
Results:
In seven of nine NAb-positive patients, IFNbeta-1a was unable to induce MxA protein. BAb were detected in 11 patients, and they preceded or paralleled the development of NAb in all the patients. The titer of NAb correlated positively with BAb titer and negatively with MxA expression level. There was also a weaker but clear correlation between BAb titers and MxA levels.
Conclusions:
NAb, in most but not all cases, inhibited the in vivo function of IFNbeta. Analysis of MxA protein in lymphocytes together with analysis of NAb is a promising marker for evaluating the biologic effects of IFNbeta treatment in MS patients.
Insights
Neutralizing antibodies (NAb) against interferon-beta (IFNbeta) can reduce treatment efficacy in MS patients by inhibiting MxA protein. Monitoring NAb and MxA levels offers a way to assess IFNbeta
Area of Science:
- Immunology
- Neuroimmunology
- Pharmacology
Background:
- Neutralizing antibodies (NAb) to interferon-beta (IFNbeta) are linked to decreased treatment efficacy in multiple sclerosis (MS).
- The biological significance of IFNbeta antibodies remains unclear, with limited comparability across detection methods.
- NAb interfere with IFNbeta's ability to induce MxA gene expression and inhibit viral growth in vitro.
Purpose of the Study:
- To prospectively investigate the development of binding antibodies (BAb) and NAb in MS patients treated with IFNbeta-1a.
- To examine the relationship between antibody development and MxA protein levels.
- To evaluate MxA protein as a marker for IFNbeta's in vivo biological activity.
Main Methods:
- A 1-year prospective study involving 20 patients with relapsing-remitting MS receiving IFNbeta-1a.
- Monitoring of binding antibodies (BAb) and neutralizing antibodies (NAb).
- Measurement of IFN-inducible MxA protein levels in peripheral blood leukocytes.
Main Results:
- IFNbeta-1a failed to induce MxA protein in most NAb-positive patients.
- Binding antibodies (BAb) were detected in 11 patients and preceded or coincided with NAb development.
- NAb titers correlated positively with BAb titers and negatively with MxA expression, with a weaker correlation for BAb and MxA.
Conclusions:
- NAb generally inhibit the in vivo biological function of IFNbeta in MS patients.
- Measuring MxA protein in lymphocytes alongside NAb analysis is a promising approach.
- This combined analysis can help evaluate the biological effects of IFNbeta treatment in MS.